-
公开(公告)号：NO994364A
公开(公告)日：1999-11-09
申请号：NO994364
申请日：1999-09-09
Applicant: BASF AG , BASF BIORESEARCH CORP
Inventor： RITTER KURT , AMBERG WILHELM , BARLOZZARI TERESA , HAUPT ANDREAS , JANSSEN BERND , KLING ANDREAS
CPC classification number: C07K5/101 , A61K38/00 , C07K5/1027 , C07K7/02
-
2.发明专利
公开(公告)号：AU6448298A
公开(公告)日：1998-09-29
申请号：AU6448298
申请日：1998-03-05
Applicant: BASF AG , BASF BIORESEARCH CORP
Inventor： RITTER KURT , AMBERG WILHELM , BARLOZZARI TERESA , HAUPT ANDREAS , JANSSEN BERND , KLING ANDREAS
Abstract: The present invention relates to novel peptides useful as anti-cancer agents. The compounds of the invention are of Formula I,A-B-D-E-F-G(I)A, B, D, and E are alpha -amino acid residues. In one embodiment, F is an azacycloalkanecarboxylic acid residue. In this embodiment, G is a monovalent radical, for example, a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group. In another embodiment, F is an azacycloalkyl group and G is a heteroaryl group connected to F by a carbon-carbon bond. In another embodiment, the invention includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
-
公开(公告)号：NO994364L
公开(公告)日：1999-11-09
申请号：NO994364
申请日：1999-09-09
Applicant: BASF AG , BASF BIORESEARCH CORP
Inventor： RITTER KURT , AMBERG WILHELM , BARLOZZARI TERESA , HAUPT ANDREAS , JANSSEN BERND , KLING ANDREAS
Abstract: The present invention relates to novel peptides useful as anti-cancer agents. The compounds of the invention are of Formula I,A-B-D-E-F-G(I)A, B, D, and E are alpha -amino acid residues. In one embodiment, F is an azacycloalkanecarboxylic acid residue. In this embodiment, G is a monovalent radical, for example, a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group. In another embodiment, F is an azacycloalkyl group and G is a heteroaryl group connected to F by a carbon-carbon bond. In another embodiment, the invention includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
-
公开(公告)号：NO994364D0
公开(公告)日：1999-09-09
申请号：NO994364
申请日：1999-09-09
Applicant: BASF AG , BASF BIORESEARCH CORP
Inventor： RITTER KURT , AMBERG WILHELM , BARLOZZARI TERESA , HAUPT ANDREAS , JANSSEN BERND , KLING ANDREAS
Abstract: The present invention relates to novel peptides useful as anti-cancer agents. The compounds of the invention are of Formula I,A-B-D-E-F-G(I)A, B, D, and E are alpha -amino acid residues. In one embodiment, F is an azacycloalkanecarboxylic acid residue. In this embodiment, G is a monovalent radical, for example, a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group. In another embodiment, F is an azacycloalkyl group and G is a heteroaryl group connected to F by a carbon-carbon bond. In another embodiment, the invention includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
-
公开(公告)号：AU4708199A
公开(公告)日：2000-02-01
申请号：AU4708199
申请日：1999-06-23
Applicant: BASF AG , BASF BIORESEARCH CORP
Inventor： RITTER KURT , JANSSEN BERND , HAUPT ANDREAS , KLING ANDREAS , BARLOZZARI TERESA , AMBERG WILHELM
Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IA-B-D-E-F-G(I)and acid salts thereof, wherein A, D, and E are alpha -amino acid residues, B is an alpha -amino acid residue or an alpha -hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a beta -hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
-
Patent Agency Ranking6.发明申请NOVEL CARBAMATES AND CARBAMIDES, PRODUCTION AND USE THEREOF AS ENDOTHELIN RECEPTOR ANTAGONISTS 审中-公开新的和氨基甲酸酯脲，生产与应用，内皮素受体拮抗剂
公开(公告)号：WO0190079A3
公开(公告)日：2002-04-04
申请号：PCT/EP0105742
申请日：2001-05-18
Applicant: BASF AG , AMBERG WILHELM , KETTSCHAU GEORG
Inventor： AMBERG WILHELM , KETTSCHAU GEORG
IPC: C07D251/22 , A61K31/44 , A61K31/505 , A61K31/506 , A61K31/519 , A61K31/53 , A61K31/5377 , A61P1/18 , A61P7/10 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P13/08 , A61P13/12 , A61P15/10 , A61P43/00 , C07D213/69 , C07D239/34 , C07D239/52 , C07D239/60 , C07D239/70 , C07D241/18 , C07D401/12 , C07D403/12 , C07D491/048 , C07D495/04
CPC classification number: C07D239/60 , C07D239/34
Abstract: The invention relates to carbamate and carbamide derivatives of formula (I), wherein the substituents have the meaning cited in the description. The invention also relates to the production and use thereof as endothelin receptor antagonists.
Abstract translation: 本发明涉及其中取代基在说明书所说明的式（I），以及它们的制备氨基甲酸酯和脲衍生物和作为内皮素受体拮抗剂使用。
-
7.发明申请CARBOXYLIC ACID DERIVATIVES COMPRISING ARYL-SUBSTITUTED NITROGEN HETEROCYCLES, THEIR PRODUCTION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS 审中-公开羧酸与芳基 - 取代的氮杂环，生产和使用AS内皮素受体拮抗剂衍生物
公开(公告)号：WO0073276A3
公开(公告)日：2001-05-10
申请号：PCT/EP0004571
申请日：2000-05-19
Applicant: BASF AG , AMBERG WILHELM , KETTSCHAU GEORG
Inventor： AMBERG WILHELM , KETTSCHAU GEORG
IPC: C07D251/14 , A61K31/4418 , A61K31/50 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/53 , A61K45/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/06 , A61P13/08 , A61P35/00 , C07D213/64 , C07D213/68 , C07D237/14 , C07D239/34 , C07D239/52 , C07D251/30 , C07D253/06
CPC classification number: C07D251/30 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/53 , C07D239/34 , C07D239/52
Abstract: The invention relates to carboxylic acid derivatives of formula (I), whereby the substituents have the meanings as explained in the description. The invention also relates to the production and use of said novel carboxylic acid derivatives as endothelin receptor antagonists.
Abstract translation: 本发明涉及羧酸的式（I）其中取代基是在说明书，制备如所解释和作为内皮素受体拮抗剂使用的衍生物。
-
公开(公告)号：WO9722621A3
公开(公告)日：1998-02-26
申请号：PCT/EP9605518
申请日：1996-12-11
Applicant: BASF AG , AMBERG WILHELM , BARLOZZARI TERESA , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , HEGE HANS GUENTHER , JANSSEN BERND , KLING ANDREAS , LIETZ HELMUT , RITTER KURT , ULLRICH MARTINA , WEYMANN JUERGEN , ZIERKE THOMAS
Inventor： AMBERG WILHELM , BARLOZZARI TERESA , BERNARD HARALD , BUSCHMANN ERNST , HAUPT ANDREAS , HEGE HANS-GUENTHER , JANSSEN BERND , KLING ANDREAS , LIETZ HELMUT , RITTER KURT , ULLRICH MARTINA , WEYMANN JUERGEN , ZIERKE THOMAS
CPC classification number: A61K38/08
Abstract: Novel peptides of the following formula (I): R1R2N-CHX-CO-A-B-D-E-(G)¿s?-K in which R?1, R2¿, A, B, D, E, G, K, X, and s have the meanings stated in the description, and the preparation thereof are described. The novel peptides have an antineoplastic effect.
-
9.发明申请INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND alpha V beta 3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY 审中-公开内皮素信号途径的抑制剂和αVβ3整合素受体拮抗剂组合治疗
公开(公告)号：WO0124827A3
公开(公告)日：2002-05-10
申请号：PCT/EP0009671
申请日：2000-10-02
Applicant: BASF AG , AMBERG WILHELM , KLING ANDREAS , HORNBERGER WILFRIED
Inventor： AMBERG WILHELM , KLING ANDREAS , HORNBERGER WILFRIED
IPC: A61K38/00 , A61K45/00 , A61K45/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P19/02 , A61P29/00 , A61P37/06 , A61P43/00 , C07D239/34 , C07D263/34 , C07D277/48 , C07D307/68 , C07D333/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07K5/02
CPC classification number: C07D263/34 , A61K38/00 , A61K45/06 , C07D239/34 , C07D277/48 , C07D307/68 , C07D333/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07K5/0202
Abstract: The invention relates to the use of an endothelin blocker in combination with an alpha v beta 3 integrin receptor antagonist for the treatment or prevention of diseases, particularly to the use of a pharmaceutical composition, comprising an endothelin blocker and an alpha v beta 3 integrin receptor antagonist, for the treatment or prevention of cardiovascular disorders, particularly for the treatment or prevention of restenosis after vessel injury or revascularisation treatment and to the pharmaceutical composition itself.
Abstract translation: 本发明涉及内皮素阻滞剂与αvβ3整联蛋白受体拮抗剂组合用于治疗或预防疾病，特别是包含内皮素阻断剂和αvβ3整联蛋白受体的药物组合物的使用 拮抗剂，用于治疗或预防心血管疾病，特别是用于治疗或预防血管损伤或血运重建治疗后的再狭窄以及药物组合物本身。
-
10.发明申请
公开(公告)号：WO9944988A3
公开(公告)日：1999-11-11
申请号：PCT/EP9901209
申请日：1999-02-25
Applicant: BASF AG , AMBERG WILHELM , JANSEN ROLF , KLINGE DAGMAR
Inventor： AMBERG WILHELM , JANSEN ROLF , KLINGE DAGMAR
IPC: C07D239/38 , A61K31/19 , A61K31/215 , A61K31/357 , A61K31/36 , A61K31/505 , A61P43/00 , C07C319/14 , C07C323/56 , C07D239/56 , C07D239/60 , C07D317/62 , C07C323/22 , C07D317/56
CPC classification number: C07C319/14 , C07D239/60
Abstract: The invention relates to a method for preparing sulfanyl-type endothelin receptor antagonists of general formula (I) wherein R represents hydroxy, alkoxy, sulfonamidyl, amino; R represents alkyl, aryl or heteroaryl, optionally substituted, and R , R , R can be the same or different and are alkyl or aryl, optionally substituted, by means of nucleophilic reaction of a carboxylic acid derivative of formula (II) with a sulfide of formula (III), X being SR or SO2R and R being alkyl or aryl, optionally substituted.
Abstract translation: 一种通式（I）Sulfanyltyp的内皮素受体拮抗剂，其中，R <1>是羟基，烷氧基，sulfonamidyl，氨基的制备方法中，R <2>是烷基，芳基或杂芳基，任选被取代，且R <3>，R <4> ，R <5>相同或独立地为烷基或芳基，任选被取代的，可通过用下式的硫化物式（II）的羧酸衍生物的亲核反应而制备（III），其中X为SR <6>或SO 2 <6>，和 [R <6>是烷基或芳基可任选被取代，式（I）的内皮素受体拮抗剂。
-
-
-
-
-
-
-
-
-
Search Results
457
records
(took 0.027 seconds)
